Cartilage degradation products as markers for evaluation of patients with rheumatic disease

Clinical and Applied Immunology Reviews

Volumn 4, Issue 4, 2004, Pages 277-294

  Christgau, Stephan ^a   Cloos, Paul A C ^b  

^a Nordic Bone   (Denmark)

^b NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

Arthritis; Biochemical markers; Cartilage matrix; Disease monitoring

Indexed keywords

AGGRECAN; ALENDRONIC ACID; ALKALINE PHOSPHATASE; ANTIRHEUMATIC AGENT; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CHONDROITIN SULFATE; COLLAGEN TYPE 1; COLLAGEN TYPE 2; HYALURONIC ACID; IBANDRONIC ACID; KERATAN SULFATE; MATRIX METALLOPROTEINASE; OSTEOCALCIN; PREDNISOLONE; PROTEOGLYCAN; TELOPEPTIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

CARTILAGE DEGENERATION; CARTILAGE MATRIX; CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; EVALUATION; HUMAN; MEDICAL DOCUMENTATION; MEDICAL RESEARCH; METABOLITE; OSTEOARTHRITIS; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

EID: 1842832094     PISSN: 15291049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cair.2004.01.003     Document Type: Review

References (67)

1. Wollheim F.A. Markers of disease in rheumatoid arthritis Curr Opin Rheumatol 12 2000 200-204
2. DeGroot J. Bank R.A. Tchetverikov I. Verzijl N. TeKoppele J.M. Molecular markers for osteoarthritis: the road ahead Curr Opin Rheumatol 14 2002 585-589
3. Stucki G. Langenegger T. Management of rheumatoid arthritis Curr Opin Rheumatol 9 1997 229-235
4. Scott D.L. Houssien D.A. Clinical and laboratory assessments in rheumatoid arthritis and osteoarthritis Br J Rheumatol 35 1996 6-9
5. Ory P.A. Interpreting radiographic data in rheumatoid arthritis Ann Rheum Dis 62 2003 597-604
6. Møller H.J. Connective tissue markers of Rheumatoid Arthritis Scand J Clin Lab Invest 58 1998 269-278
7. Christgau S. Cloos P. Christiansen C. Bang Henriksen D. Mo J. Isomerized aggrecan fragments are released during cartilage degradation and can be measured in serum Osteoarthritis Cartilage 10 Suppl. 2002 S12
8. Deberg M. Labasse A. Christgau S. Henriksen D. Reginster J.Y. Henrotin Y. Cartilage degradation and oxidative damage in osteoarthritic and rheumatoid arthritic patients Osteoarthritis Cartilage 11 Suppl. 2003 S15
9. Garnero P. Piperno M. Gineyts E. Christgau S. Delmas P.D. Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage Ann Rheum Dis 60 2001 619-626
10. Garnero P. Gineyts E. Christgau S. Finck B. Delmas P.D. Baseline levels of urinary glucosyl-galactosyl pyridinoline and type II collagen C-telopeptide are associated with progression of joint destruction in patients with early rheumatoid arthritis Arthritis Rheum 46 2002 21-30
11. Christgau S. Garnero P. Fledelins C. Moniz C. Ensig M. Gineyts E. et al. Collagen type II degradation products in urine as an index of cartilage degradation Bone 29 2001 209-215
12. Østergård M. Szkudlarek M. Imaging in rheumatoid arthritis-why MRI and ultrasonography can no longer be ignored Scand J Rheumatol 32 2003 63-73
13. Brandi M.L. Gennari L. Cerinic M.M. Becherini L. Falchetti A. Masi L. et al. Genetic markers of osteoarticular disorders: facts and hopes Arthritis Res 3 2001 270-280
14. Archer C.W. Francis-West P. The chondrocyte Int J Biochem Cell Biol 35 2003 401-404
15. van der Kraan P.M. Buma P. van Kuppevelt T. van den Berg W.B. Interaction of chondrocytes, extracellular matrix and growth factors: relevance for articular cartilage tissue engineering Osteoarthritis Cartilage 10 2002 631-637
16. Martin J.A. Buckwalter J.A. Aging, articular cartilage chondrocyte senescence and osteoarthritis Biogerontology 3 2002 257-264
17. Prockop D.J. Kivirikko K.I. Collagens: Molecular biology, diseases and potential for therapy Annu Rev Biochem 64 1995 203-234
18. Nelson F. Dahlberg L. Laverty S. Reiner A. Pidoux I. Ionescu M. et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis J Clin Invest 102 1998 2115-2125
19. Garnero P. Ayral X. Rousseau J.-C. Christgau S. Sandell L. Delmas P.D. et al. Uncoupling of type II collagen metabolism predicts progression of joint damage in patients with knee osteoarthritis Arthritis Rheum 46 2002 2613-2624
20. Eyre D.R. The collagens of articular cartilage Semin Arthritis Rheum 3 Suppl 2 1991 2-11
21. Takahashi M. Kushida K. Hoshino H. Suzuki M. Sano M. Miyamoto S. et al. Concentrations of pyridinoline and deoxypyridinoline in joint tissues from patients with osteoarthritis or rheumatoid arthritis Ann Rheum Dis 55 1996 324-327
22. Furumitsu Y. Inaba M. Yukioka K. Yukioka M. Kumeda Y. Azuma Y. et al. Levels of serum and synovial fluid pyridinium crosslinks in patients with rheumatoid arthritis J Rheumatol 27 2000 64-70
23. Chu Q. Lopez M. Hayashi K. Elevation of a collagenase generated type II collagen neoepitope and proteoglycan epitopes in synovial fluid following induction of joint instability in the dog Osteoarthritis Cartilage 10 2002 662-669
24. Lou W. Gou C. Zheng J. Chen T.L. Wang P.Y. Vertel B.M. et al. Aggrecan from start to finish J Bone Miner Metab 18 2000 51-56
25. Hardingham T.E. Fosang A.J. The structure of aggrecan and its turnover in cartilage J Rheumatol 22 Suppl 43 1995 89-90
26. Fawthrop F. Yaqub R. Belcher C. Bayliss M. Ledingham J. Doherty M. Chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in progressive versus non-progressive osteoarthritis Ann Rheum Dis 56 1997 119-122
27. Singer I.I. Scott S. Kawka D.W. Bayne E.K. Weidner J.R. Williams H.R. Mumford R.A. et al. Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis Osteoarthritis Cartilage 5 1997 407-418
28. Lark M.W. Bayne E.K. Lohmander L.S. Aggrecan degradation in osteoarthritis and rheumatoid arthritis Acta Orthop Scand Suppl 266 1995 92-97
29. Müller G. Michel A. Altenburg E. COMP (Cartilage Oligomeric Protein) is synthesized in ligament, tendon, meniscus and articular cartilage Connect Tissue Res 39 1998 233-244
30. Dodge G.R. Hawkins D. Boesler E. Sakai L. Jimenez S.A. Production of cartilage oligomeric matrix protein (COMP) by cultured human dermal and synovial fibroblasts Osteoarthritis Cartilage 6 1998 435-440
31. Di Cesare P.E. Fang C. Leslie M.P. Tulli H. Perris R. Carlson C.S. Expression of cartilage oligomeric matrix protein (COMP) by embryonic and adult osteoblasts J Orthop Res 18 2000 713-720
32. Petersson I.F. Boegård T. Svensson B. Heinegård D. Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint Br J Rheumatol 37 1998 46-50
33. Vilim V. Vytasek R. Olejarova M. Machacek S. Gatterova J. Prochazka B. Kraus V.B. Pavelka K. Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis Osteoarthritis Cartilage 9 2002 612-618
34. Skoumal M. Kolarz G. Klingler A. Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis Scand J Rheumatol 32 2003 156-161
35. Dragomir A.D. Kraus V.B. Renner J.B. Luta G. Clark A. Vilim V. et al. Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology Osteoarthritis Cartilage 10 2002 687-691
36. Carlson C.S. Guilak F. Vail T.P. Gardin J.F. Kraus V.B. Synovial fluid biomarker levels predict articular cartilage damage following complete medial meniscectomy in the canine knee J Orthop Res 20 2002 92-100
37. Liao Q. Kleeff J. Xiao Y. Di Cesare P.E. Korc M. Zimmermann A. et al. COMP is selectively up-regulated in degenerating acinar cells in chronic pancreatitis and in chronic-pancreatitis-like lesions in pancreatic cancer Scand J Gastroenterol 38 2003 207-215
38. Harvey S. Weisman M. O'Dell J. Scott T. Krusemeier M. Visor J. et al. Chondrex: new marker of joint disease Clin Chem 44 1998 509-516
39. Kirkpatrick R.B. Emery J.G. Connor J.R. Dodds R. Lysko P.G. Rosenber M. Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages Exp Cell Res 237 1997 46-54
40. Cawston T.E. Metalloproteinase inhibitors and the prevention of connective tissue breakdown Pharmacol Ther 70 1996 163-182
41. Posthumus M.D. Limburg P.C. Westra J. van Leeuwen M.A. van Rijswijk M.H. Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis Clin Exp Rheumatol 21 2003 465-472
42. Brennan F.M. Browne K.A. Green P.A. Jaspar J.M. Maini R.N. Feldmann M. Reduction of serum matrix MMP 1 and MMP 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy Br J Rheumatol 36 1997 643-650
43. Green M.J. Gough A.K. Devlin J. Smith J. Astin P. Taylor D. et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis Rheumatology (Oxford) 42 2003 83-88
44. Ishiguro N. Ito T. Obata K. Fujimoto N. Iwata H. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis J Rheumatol 23 1996 1599-1604
45. Manicourt D.H. Fujimoto N. Obata K. Thonar E.J. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation Arthritis Rheum 38 1995 1031-1039
46. Abad V. Meyers J.L. Weise M. Gafni R.I. Barnes K.M. Nilsson O. The role of the resting zone in growth plate chondrogenesis Endocrinology 143 2002 1851-1857
47. Verzijl N. DeGroot J. Ben Z.C. Brau-Benjamin O. Maroudas A. Bank R.A. et al. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis Arthritis Rheum 46 2002 114-123
48. Cloos P.A.C. Christgau S. Non-enzymatic covalent modifications of proteins: mechanisms, physiological consequences and clinical applications Matrix Biol 21 2002 39-52
49. Garnero P. Delmas P.D. Biomarkers in osteoarthritis Curr Opin Rheumatol 15 2003 641-646
50. Christgau S. Cloos P.A.C. Current and future applications of bone turnover markers Clin Lab 49 2003 439-446
51. Bettica P. Cline G. Hart D.J. Meyer J. Spector T.D. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study Arthritis Rheum 46 2002 3178-3184
52. Blair H.C. Zaidi M. Schlessinger P.H. Mechanisms balancing skeletal synthesis and degradation Biochem J 364 2002 329-341
53. Cloos P.A.C. Fledelius C. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential Biochem J 345 2000 473-480
54. Christgau S. Bitsch-Jensen O. Hanover Bjarnason N. Henriksen E. Qvist P. Alexandersen P. Henriksen D. Serum crosslaps for monitoring the response in individuals undergoing antiresorptive therapy Bone 26 2000 505-511
55. Eastell R. Barton I. Hannon R.A. Chines A. Garnero P. Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate J Bone Miner Res 18 2003 1051-1056
56. Bruyere O. Collette J. Delmas P. Rouillon A. Roux C. Seidel L. et al. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women Maturitas 44 2003 259-265
57. De Ceuninck F. Sabatini M. Renoux V. de Nanteuil G. Pastoureau P. Urinary collagen type II C-telopeptide fragments are sensitive markers of matrix metalloproteinase-dependent cartilage degradation in rat adjuvant-induced arthritis J Rheumatol 30 2003 1561-1564
58. Leff R.L. Elias I. Ionescu M. Reiner A. Poole A.R. Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor J Rheumatol 30 2003 544-549
59. Shingleton W.D. In vitro model of human articular cartilage degradation Methods Mol Biol 225 2003 99-106
60. Vingsbo-Lundberg C. Saxne T. Olsson H. Holmdahl R. Increased serum levels of cartilage oligomeric matrix protein in chronic erosive arthritis in rats Arthritis Rheum 41 1998 544-550
61. Seed M.P. The assessment of inflammation, cartilage matrix, and bone loss in experimental monoarticular arthritis of the rat Methods Mol Biol 225 2003 161-174
62. Lindhorst E. Vail T.P. Guilak F. Wang H. Setton L.A. Vilim V. et al. Longitudinal characterization of synovial fluid biomarkers in the canine meniscectomy model of osteoarthritis J Orthop Res 18 2000 269-280
63. Harrison B.J. Symmons D.P. Barrett E.M. Silman A.J. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis J Rheumatol 25 1998 2324-2330
64. Hansen M. Pødenphant J. Florescu A. Stoltenberg M. Borch A. Kluger E. et al. A randomized trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects Ann Rheum Dis 58 1999 713-718
65. Jensen T. Hansen M. Stoltenberg M. Christgau S. Sommarin Y. Lorenzen I. Connective tissue metabolism in patients with active rheumatoid arthritis during treatment with prednisolone and/or DMARD Ann Rheum Dis 59 Suppl 1 2001 108
66. Sharif M. Saxne T. Shepstone L. Kirwan J.R. Elson C.J. Heinegård D. et al. Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint Br J Rheumatol 34 1995 306-310
67. Lehmann H.J. Mouritzen U. Christgau S. Cloos P. Christiansen C. The effects of bisphosphonates on CartiLaps: a new marker for cartilage degradation Ann Rheum Dis 61 2002 530-533